Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment

Archives of Neurology

Volumn 65, Issue 9, 2008, Pages 1231-1236

  Caselli, Richard J ^a,c   Chen, Kewei ^a,b,c   Lee, Wendy ^a,b,c   Alexander, Gene E ^a,c,d   Reiman, Eric M ^a,b,c  

^a MAYO CLINIC   (United States)

^b BANNER ALZHEIMER S INSTITUTE   (United States)

^c ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^d University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGE; AGED; ALGORITHM; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN DISEASE; BRAIN MAPPING; BRAIN METABOLISM; CEREBRAL HYPOMETABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; GENOTYPE; GLUCOSE BRAIN LEVEL; HUMAN; LONGITUDINAL STUDY; MALE; METABOLIC DISORDER; METABOLIC RATE; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; PATIENT EDUCATION; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECALL; SEX DIFFERENCE; TEMPORAL CORTEX; VERBAL MEMORY;

AGED; AMNESIA; BRAIN; COGNITION DISORDERS; COHORT STUDIES; FEMALE; FORECASTING; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED;

EID: 51649088252     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.1     Document Type: Article

References (34)

1. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
3. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397-405.
4. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-681.
5. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord. 2006;22(4):312-319.
6. Petersen RC, Thomas RG, Grundman M, et al; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
7. Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology. 2007;27(6):578-584.
8. Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein ε4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64(9):1306-1311.
9. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
10. Caselli RJ, Reiman EM, Osborne D, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004;62(11):1990-1995.
11. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
12. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-548.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
15. 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function. J Cereb Blood Flow Metab. 1998;18(7):716-723.
16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238-1248.
17. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159(5):738-745.
18. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758.
19. Reiman EM, Caselli RJ, Alexander GE, Chen KW. Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin Neurosci Res. 2001;1(3):194-206.
20. Reiman EM, Chen KW, Alexander GE, et al. Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102(23):8299-8302.
21. Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. New York, NY: Thieme Medical Publishers; 1988.
22. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273(12):942-947.
23. Small GW, Ercoli LM, Silverman DHS, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037-6042.
24. de Leon MJ, Mosconi L, Blennow K, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer disease. Ann N Y Acad Sci. 2007;1097:114-145.
25. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun Study. JAMA. 1996;275(7):528-532.
26. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E ε4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol. 1998;153(1):152-155.
27. Reiman EM, Chen KW, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101(1):284-289.
28. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Bäckman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol. 2000;57(6):839-844.
29. Smith GE, Pankratz VS, Negash S, et al. A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms? Neurology. 2007;69(2):133-139.
30. Locke PA, Conneally PM, Tanzi RE, Gusella JF, Haines JL. Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. Genet Epidemiol. 1995;12(1):83-92.
31. Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet. 1996;58(3):574-584.
32. Reiman EM, Caselli RJ, Chen KW, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(6):3334-3339.
33. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467-473.
34. Reisberg B, Prichep L, Mosconi L, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement. 2008;4(suppl 1):S98-S108.